Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Detalles Bibliográficos
Autores principales: Saleh, Mansoor N., Patel, Manish R., Bauer, Todd M., Goel, Sanjay, Falchook, Gerald S., Shapiro, Geoffrey I., Chung, Ki Y., Infante, Jeffrey R., Conry, Robert M., Rabinowits, Guilherme, Hong, David S., Wang, Judy S., Steidl, Ulrich, Walensky, Loren D., Naik, Gurudatta, Guerlavais, Vincent, Vukovic, Vojislav, Annis, D. Allen, Aivado, Manuel, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Corrections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361214/
https://www.ncbi.nlm.nih.gov/pubmed/35045962
http://dx.doi.org/10.1158/1078-0432.CCR-21-4241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361214/
https://www.ncbi.nlm.nih.gov/pubmed/35045962
http://dx.doi.org/10.1158/1078-0432.CCR-21-4241

Ejemplares similares